Key statistics
On Friday, Akero Therapeutics Inc (0K4:BER) closed at 24.89, 132.62% above the 52 week low of 10.70 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.06 |
---|---|
High | 25.11 |
Low | 24.53 |
Bid | 24.86 |
Offer | 25.36 |
Previous close | 25.38 |
Average volume | 121.50 |
---|---|
Shares outstanding | 69.43m |
Free float | 58.95m |
P/E (TTM) | -- |
Market cap | 1.95bn USD |
EPS (TTM) | -3.41 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 19:30 BST.
More ▼
- Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
- Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
- Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
- Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
- Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
- Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
More ▼